Teitsma, Xavier M
Yang, Wei
Jacobs, Johannes W G
Pethö-Schramm, Attila
Borm, Michelle E A
Harms, Amy C
Hankemeier, Thomas
van Laar, Jacob M
Bijlsma, Johannes W J
Lafeber, Floris P J G
Article History
Received: 17 July 2018
Accepted: 20 September 2018
First Online: 15 October 2018
Ethics approval and consent to participate
: The medical ethics research committee of the University Medical Center Utrecht approved the study for all participating hospitals. All patients signed informed consent before study entry.
: Not applicable.
: The department of the authors who included patients (JWGJ and JWJB) in the U-Act-Early trial received reimbursements from Roche Nederland BV. JWJB reported grants and fees from Roche, AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and UCB. JMvL received fees from Arthrogen, MSD, Pfizer, Eli Lilly, and BMS and research grants from Astra Zeneca, Roche-Genentech. FPJGL reports grants from Roche. AP-S is an employee of F Hoffmann-La Roche and MEAB is an employee of Roche Nederland BV. XMT, WY, ACH, and TH declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.